LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 25,000 ADSs (each representing 65 ordinary shares of no par value in the market) at a price of US$3.8749 per ADS.
OKYO Pharma Limited - PDMR Dealing
Globe Newswire -
Wed May 18, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Amazon%20-%20Image%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/The%20CoreWeave%20logo%20displayed%20on%20a%20smartphone%20screen_%20Image%20by%20Robert%20Way%20via%20Shutterstock_.jpg)
